Compare Stocks

Date Range: 

 Molecular TemplatesAC ImmuneVerastemXBiotechAvadel Pharmaceuticals
SymbolNASDAQ:MTEMNASDAQ:ACIUNASDAQ:VSTMNASDAQ:XBITNASDAQ:AVDL
Price Information
Current Price$8.81$6.15$2.85$17.04$8.17
52 Week RangeBuyBuyBuyN/ABuy
MarketRank™
Overall Score2.01.31.11.01.5
Analysis Score3.43.51.50.03.5
Community Score2.62.42.63.12.4
Dividend Score0.00.00.00.00.0
Ownership Score3.30.00.80.00.8
Earnings & Valuation Score0.60.60.61.90.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$14.50$16.00$3.00N/A$18.75
% Upside from Price Target64.59% upside160.16% upside5.26% upsideN/A129.50% upside
Trade Information
Market Cap$494.14 million$446.82 million$489.25 million$510.91 million$477.66 million
Beta2.080.820.721.51.55
Average Volume443,700749,9842,736,87596,216440,739
Sales & Book Value
Annual Revenue$22.27 million$111.75 million$17.46 millionN/A$59.22 million
Price / Sales22.194.0028.02N/A8.07
CashflowN/A$0.69 per shareN/AN/AN/A
Price / CashN/A8.97N/AN/AN/A
Book Value$2.79 per share$4.06 per share$0.09 per share$18.20 per share($0.78) per share
Price / Book3.161.5131.67N/A-10.47
Profitability
Net Income$-69,420,000.00$45.74 million$-149,210,000.00$668.63 million$-33,230,000.00
EPS($1.26)$0.60($2.00)N/A($0.89)
Trailing P/E RatioN/AN/AN/A1.1840.85
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-428.65%-392.56%-590.19%N/A38.70%
Return on Equity (ROE)-111.43%-23.88%-189.37%-7.07%-33.91%
Return on Assets (ROA)-56.35%-21.85%-67.69%-6.67%-11.75%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.18%N/A0.45%N/A0.74%
Current Ratio3.21%18.10%5.02%18.28%12.24%
Quick Ratio3.21%18.10%4.80%18.28%12.24%
Ownership Information
Institutional Ownership Percentage60.73%27.68%42.15%14.79%53.78%
Insider Ownership Percentage38.20%N/A2.90%30.98%1.41%
Miscellaneous
Employees228125489132
Shares Outstanding56.09 million72.65 million171.67 million29.98 million58.47 million
Next Earnings Date5/10/2021 (Estimated)8/4/2021 (Estimated)N/A5/10/2021 (Estimated)5/10/2021 (Confirmed)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Zacks: Brokerages Expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) Will Announce Earnings of -$0.32 Per ShareZacks: Brokerages Expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) Will Announce Earnings of -$0.32 Per Share
americanbankingnews.com - May 5 at 5:18 PM
Avadel Pharmaceuticals (AVDL) Set to Announce Quarterly Earnings on MondayAvadel Pharmaceuticals (AVDL) Set to Announce Quarterly Earnings on Monday
americanbankingnews.com - May 3 at 9:30 AM
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10thAvadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
markets.businessinsider.com - April 29 at 10:31 AM
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10thAvadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
finance.yahoo.com - April 29 at 10:31 AM
Avadel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AVDL)Avadel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AVDL)
americanbankingnews.com - April 28 at 9:44 AM
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Given Average Recommendation of "Buy" by AnalystsAvadel Pharmaceuticals plc (NASDAQ:AVDL) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - April 24 at 4:54 AM
Avadels Formulated Sodium Oxybate Shows Improved Sleepiness, Sleep Quality In Narcolepsy PatientsAvadel's Formulated Sodium Oxybate Shows Improved Sleepiness, Sleep Quality In Narcolepsy Patients
finance.yahoo.com - April 19 at 12:40 PM
Avadel Presents New Data from its Pivotal REST-ON...Avadel Presents New Data from its Pivotal REST-ON...
benzinga.com - April 18 at 8:01 PM
 Brokerages Anticipate Avadel Pharmaceuticals plc (NASDAQ:AVDL) to Announce -$0.32 EPS Brokerages Anticipate Avadel Pharmaceuticals plc (NASDAQ:AVDL) to Announce -$0.32 EPS
americanbankingnews.com - April 18 at 4:44 PM
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium ...Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium ...
apnews.com - April 17 at 12:36 PM
Head-To-Head Analysis: Avadel Pharmaceuticals (NASDAQ:AVDL) versus Xeris Pharmaceuticals (NASDAQ:XERS)Head-To-Head Analysis: Avadel Pharmaceuticals (NASDAQ:AVDL) versus Xeris Pharmaceuticals (NASDAQ:XERS)
americanbankingnews.com - April 15 at 6:54 AM
Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021
finance.yahoo.com - April 8 at 12:59 PM
Could The Avadel Pharmaceuticals plc (NASDAQ:AVDL) Ownership Structure Tell Us Something Useful?Could The Avadel Pharmaceuticals plc (NASDAQ:AVDL) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - March 29 at 8:17 AM
Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on ...Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on ...
apnews.com - March 19 at 4:45 AM
Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31stAvadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st
finance.yahoo.com - March 18 at 8:18 AM
Revenue Downgrade: Heres What Analysts Forecast For Avadel Pharmaceuticals plc (NASDAQ:AVDL)Revenue Downgrade: Here's What Analysts Forecast For Avadel Pharmaceuticals plc (NASDAQ:AVDL)
nasdaq.com - March 11 at 9:34 AM
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 ...Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 ...
apnews.com - March 10 at 1:13 AM
Avadel Pharmaceuticals plc (AVDL) Q4 2020 Earnings Call TranscriptAvadel Pharmaceuticals plc (AVDL) Q4 2020 Earnings Call Transcript
fool.com - March 9 at 3:32 PM
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results Nasdaq:AVDLAvadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results Nasdaq:AVDL
compsmag.com - March 9 at 2:58 PM
Avadel: Q4 Earnings SnapshotAvadel: Q4 Earnings Snapshot
finance.yahoo.com - March 9 at 9:54 AM
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsAvadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 9 at 9:54 AM
Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an ...Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an ...
apnews.com - March 5 at 12:52 AM
Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 Young Investigators Research ForumAvadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 Young Investigators Research Forum
finance.yahoo.com - March 4 at 9:51 AM
Argobio announces its launch with 50 M€ to create…Argobio announces its launch with 50 M€ to create…
pharmiweb.com - March 3 at 7:43 AM
Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults ...Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults ...
apnews.com - March 2 at 10:07 AM
DateCompanyBrokerageAction
4/27/2021Molecular TemplatesBank of AmericaInitiated Coverage
4/15/2021Molecular TemplatesOppenheimerLower Price Target
4/6/2021Molecular TemplatesJefferies Financial GroupBoost Price Target
2/1/2021Molecular TemplatesUBS GroupInitiated Coverage
3/25/2020Molecular TemplatesStifel NicolausInitiated Coverage
2/27/2020Molecular TemplatesBarclaysInitiated Coverage
11/13/2019Molecular TemplatesCowenReiterated Rating
12/11/2018Molecular TemplatesCIBCInitiated Coverage
12/10/2018Molecular TemplatesLADENBURG THALM/SH SHReiterated Rating
11/15/2018Molecular TemplatesEvercore ISIInitiated Coverage
10/8/2018Molecular TemplatesLaidlawInitiated Coverage
3/30/2021AC ImmuneHC WainwrightBoost Price Target
11/12/2018AC ImmuneSVB LeerinkInitiated Coverage
4/8/2021VerastemCantor FitzgeraldReiterated Rating
8/2/2019VerastemB. RileySet Price Target
6/20/2019VerastemBTIG ResearchDowngrade
5/14/2019VerastemRoth CapitalLower Price Target
5/10/2019VerastemRaymond JamesDowngrade
7/27/2018VerastemSeaport Global SecuritiesSet Price Target
4/7/2020XBiotechPiper SandlerLower Price Target
12/11/2019XBiotechPiper Jaffray CompaniesBoost Price Target
11/9/2020Avadel PharmaceuticalsLifesci CapitalReiterated Rating
8/11/2020Avadel PharmaceuticalsCi CapitalReiterated Rating
4/3/2020Avadel PharmaceuticalsCraig HallumBoost Price Target
8/7/2018Avadel PharmaceuticalsJMP SecuritiesDowngrade
8/7/2018Avadel PharmaceuticalsSunTrust BanksDowngrade
(Data available from 5/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.